GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

A combination of three medications—dapagliflozin, liraglutide and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Aug 2016

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

In an attempt to correct defects in the energy generation that contribute to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure.

2 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

When Amy Sweat was 19 years old, while she was in the hospital recovering from surgery, she was diagnosed with Type 2 diabetes. Ms. Sweat was treated for her diabetes, first on oral drugs, then on increasingly larger doses of insulin, but the years went by and she never was able to achieve good blood sugar control.

6 Jul 2016

Appetite hormone CART helps increase insulin secretion, reduce glucagon production

The study shows that the appetite hormone CART not only controls the sensation of satiety, but it also helps increase insulin secretion and decrease glucagon production.

30 Jun 2016

Empagliflozin offers long-term renal protection in Type 2 diabetes

The sodium-glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of the EMPA-REG OUTCOME trial.

16 Jun 2016

Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Findings of the LEADER trial show that liraglutide treatment may confer a reduced risk of cardiovascular events in patients with Type 2 diabetes and a high vascular risk.

15 Jun 2016

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes.

14 Jun 2016

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.

12 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

PYY hormone may offer effective treatment for type 2 diabetes

Researchers at the Norwegian University of Science and Technology and Oxford University have found a hormone that may offer an effective treatment for type 2 diabetes.

20 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.

From Bruker BioSpin Group 11 May 2016

Study helps discover new treatments for type 2 diabetes in men with low testosterone

Doctors have long known that men with low testosterone are at greater risk for developing type 2 diabetes. For the first time, researchers have identified how testosterone helps men regulate blood sugar by triggering key signaling mechanisms in islets, clusters of cells within the pancreas that produce insulin. The findings, co-authored by Tulane University researchers, are published in the journal

29 Apr 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016

Study offers clearer understanding of how obese people can sustain weight loss

Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved in obesity and especially weight loss in obesity. It is now possible to offer overweight people a clearer understanding of how to sustain weight loss.

16 Apr 2016

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

Researchers have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes.

12 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

Liraglutide drug makes highly desirable foods less appealing to people

Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.

5 Apr 2016

Adding liraglutide to diet and exercise plan may help people lose weight, reduce diabetes risk

For people with prediabetes who are overweight or obese, adding 3.0 mg of liraglutide for three years to a diet and exercise plan may lead to major health improvements, new industry-sponsored research suggests. The results will be presented Monday, April 4, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

5 Apr 2016

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

Study shows diabetes drug ineffective in improving condition of patients with advanced heart failure

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

Appetite hormone CART helps increase insulin secretion, reduce glucagon production

Empagliflozin offers long-term renal protection in Type 2 diabetes

Liraglutide cardioprotective in high-risk Type 2 diabetes patients

Liraglutide drug effectively decreases cardiovascular disease risk in type 2 diabetes patients

Liraglutide enhances high-dose insulin treatment in Type 2 diabetes

New technique could help reduce chances of drug failure during later stages of clinical trials

PYY hormone may offer effective treatment for type 2 diabetes

Clinical study shows sitagliptin drug not effective in treating NAFLD

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

Study helps discover new treatments for type 2 diabetes in men with low testosterone

GLP-1 receptor agonist may benefit high-risk diabetes

Study offers clearer understanding of how obese people can sustain weight loss

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

Liraglutide drug makes highly desirable foods less appealing to people

Adding liraglutide to diet and exercise plan may help people lose weight, reduce diabetes risk

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in